Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC

Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, discusses the results of the Phase I/II LIBRETTO-001 trial (NCT03157128), which assessed the safety and preliminary efficacy of selpercatinib in patients with RET fusion+ non-small cell lung cancer (NSCLC). 218 patients with prior platinum chemotherapy and 48 treatment-naïve patients were enrolled. Treatment with selpercatinib resulted in an improvement in objective response rate (ORR) and a well-tolerated safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Benjamin Besse, MD, PhD has received sponsored research funds from 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals.